Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More … (NCT06274788) | Clinical Trial Compass
RecruitingNot Applicable
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
United States40 participantsStarted 2024-12-15
Plain-language summary
This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
Who can participate
Age range1 Day – 17 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient's parent(s) or legal guardian(s) has provided a signed and dated Informed Consent Form (ICF).
✓. Pediatric patient (\<18 years) has been diagnosed with PNAC, defined as direct or conjugated bilirubin (DBil) ≥ 2.0 mg/dL with no other known cause of liver dysfunction at the time of enrollment and is expected to require Omegaven treatment for at least eight weeks.
✓. Patient has oral or enteral feeding intolerance or at least one gastrointestinal disorder requiring PN.
Exclusion criteria
✕. Patient has received Omegaven within four weeks before inclusion in the study
✕. Patient has any other known cause of chronic liver disease such as hepatitis C, cystic fibrosis, biliary atresia, alpha-1-antitrypsin deficiency, passive hepatic congestion due to heart failure, etc.
✕. Patient has known cirrhosis (liver biopsy is not required under this protocol).
✕. Patient has been previously diagnosed with, or has prior evidence of, portal vein thrombosis.
✕. Patient has previously received a liver-only or liver-inclusive transplant.
✕. Patient has hemodynamic instability due to any major cardiac anomaly.
✕. Patient has a major life-threatening disease (e.g., sepsis requiring high-dose vasopressors, acute respiratory distress syndrome, veno-occlusive disease, cancer).
✕
What they're measuring
1
Incidence of essential fatty acid deficiency (EFAD)